Skip to main content

Lynx1 Capital Management LP

13F filer · CIK 0001910456
Reported Aug 13, 2026
Net buyer this quarter
13F portfolio value$866MU.S. long equity reported on 13F
Positions276 new · 2 closed
Net flow last quarter+$18.1MBuys minus sells
Top 10 positions weight98.8%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 13, 202627 positions
GHRSGH Research PLC$357M41.19%21.38%+23.2%Q2 2023
CGEMCullinan Therapeutics, Inc.$163M18.86%13.93%Not reportedQ2 2023
STOKStoke Therapeutics, Inc.$132M15.27%6.47%-15.2%Q3 2023
AGIOAgios Pharmaceuticals, Inc.$127M14.62%5.72%+30.5%Q4 2025
CCCCC4 Therapeutics, Inc.$34.2M3.95%5.96%+4.7%Q3 2023
KRROKorro Bio, Inc.$20.3M2.34%10.46%Not reportedQ2 2024
TCRXTScan Therapeutics, Inc.$7.86M0.91%33.45%Not reportedQ2 2023
DTILPrecision Biosciences Inc$7.47M0.86%3.60%-3.5%Q4 2024
NEUPNeuphoria Therapeutics Inc.$3.83M0.44%16.18%Not reportedQ4 2024
PASGPassage BIO, Inc.$3.29M0.38%20.94%+8.0%Q1 2022
CGONCG Oncology, Inc.$2.23M0.26%0.04%-0.6%Q4 2025
PLRXPliant Therapeutics, Inc.$2.05M0.24%2.90%NewQ2 2026
TRDAEntrada Therapeutics, Inc.$1.31M0.15%0.46%-15.6%Q4 2025
VYNEYarrow Bioscience, Inc.$1.06M0.12%Not reportedNot reportedQ2 2024
PRQRProQR Therapeutics N.V.$970K0.11%0.49%+661.3%Q4 2025
TRAWTraws Pharma, Inc.$472K0.05%3.67%+3610.5%Q1 2026
FHTXFoghorn Therapeutics Inc.$301K0.03%0.10%NewQ2 2026
DNLIDenali Therapeutics Inc.$300K0.03%0.01%-99.4%Q3 2025
XNCRXencor Inc$293K0.03%0.02%-96.6%Q4 2025
ABSIAbsci Corp$246K0.03%0.01%Not reportedQ1 2026
HOWLWerewolf Therapeutics, Inc.$237K0.03%1.35%Not reportedQ4 2025
IMTXImmatics N.V.$235K0.03%0.02%-89.3%Q4 2025
AVTXAvalo Therapeutics, Inc.$187K0.02%0.02%NewQ2 2026
BOLTBolt Biotherapeutics, Inc.$119K0.01%1.60%Not reportedQ1 2026
NUVBNuvation Bio Inc.$91K0.01%0.00%NewQ2 2026
EPRXEupraxia Pharmaceuticals Inc.$66.1K0.01%0.02%NewQ2 2026
IKTInhibikase Therapeutics, Inc.$40.6K0.00%0.02%NewQ2 2026
Q1 2026Reported May 4, 202623 positions
STOKStoke Therapeutics, Inc.$155M24.51%7.65%-11.9%Q3 2023
GHRSGH Research PLC$151M23.92%17.35%+3.4%Q2 2023
CGEMCullinan Therapeutics, Inc.$127M20.13%14.59%Not reportedQ2 2023
AGIOAgios Pharmaceuticals, Inc.$88.3M13.96%4.40%+3179.9%Q4 2025
DNLIDenali Therapeutics Inc.$36.1M5.71%1.19%+8.1%Q3 2025
CCCCC4 Therapeutics, Inc.$18.4M2.91%6.73%-1.4%Q3 2023
KRROKorro Bio, Inc.$17.4M2.75%10.67%+126.9%Q2 2024
TCRXTScan Therapeutics, Inc.$8.1M1.28%33.45%Not reportedQ2 2023
XNCRXencor Inc$6.47M1.02%0.72%-24.0%Q4 2025
DTILPrecision Biosciences Inc$5.42M0.86%3.82%-0.9%Q4 2024
PASGPassage BIO, Inc.$4.9M0.77%19.44%Not reportedQ1 2022
NEUPNeuphoria Therapeutics Inc.$3.56M0.56%16.28%0.0%Q4 2024
TRDAEntrada Therapeutics, Inc.$2.67M0.42%0.55%+309.5%Q4 2025
CGONCG Oncology, Inc.$2.14M0.34%0.04%Not reportedQ4 2025
IMTXImmatics N.V.$2.14M0.34%0.16%-76.5%Q4 2025
DSGNDesign Therapeutics, Inc.$1.27M0.20%0.19%+71.9%Q1 2025
VYNEYarrow Bioscience, Inc.$973K0.15%Not reportedNot reportedQ2 2024
HOWLWerewolf Therapeutics, Inc.$548K0.09%1.35%+0.3%Q4 2025
IBIOiBio, Inc.$129K0.02%0.20%Not reportedQ1 2024
BOLTBolt Biotherapeutics, Inc.$124K0.02%1.60%NewQ1 2026
PRQRProQR Therapeutics N.V.$111K0.02%0.07%Not reportedQ4 2025
ABSIAbsci Corp$63.7K0.01%0.01%NewQ1 2026
TRAWTraws Pharma, Inc.$27.6K0.00%0.15%NewQ1 2026
Q4 2025Reported Feb 17, 202622 positions
STOKStoke Therapeutics, Inc.$172M34.73%9.17%Not reportedQ3 2023
GHRSGH Research PLC$132M26.75%16.78%+21.0%Q2 2023
CGEMCullinan Therapeutics, Inc.$92.8M18.78%14.88%+55.5%Q2 2023
DNLIDenali Therapeutics Inc.$28.7M5.81%1.11%+564.4%Q3 2025
CCCCC4 Therapeutics, Inc.$13.6M2.74%7.32%Not reportedQ3 2023
XNCRXencor Inc$10.8M2.19%0.98%NewQ4 2025
IMTXImmatics N.V.$9.68M1.96%0.69%NewQ4 2025
TCRXTScan Therapeutics, Inc.$8.02M1.62%33.45%+2.1%Q2 2023
PASGPassage BIO, Inc.$7.36M1.49%19.60%Not reportedQ1 2022
KRROKorro Bio, Inc.$5.43M1.10%7.20%Not reportedQ2 2024
DTILPrecision Biosciences Inc$4.13M0.84%4.13%-4.7%Q4 2024
NEUPNeuphoria Therapeutics Inc.$3.4M0.69%16.28%Not reportedQ4 2024
AGIOAgios Pharmaceuticals, Inc.$2.17M0.44%0.14%NewQ4 2025
CGONCG Oncology, Inc.$1.31M0.27%0.04%NewQ4 2025
ARWRArrowhead Pharmaceuticals, Inc.$800K0.16%0.01%NewQ4 2025
DSGNDesign Therapeutics, Inc.$652K0.13%0.12%+5.4%Q1 2025
TRDAEntrada Therapeutics, Inc.$531K0.11%0.14%NewQ4 2025
HOWLWerewolf Therapeutics, Inc.$416K0.08%1.35%NewQ4 2025
MPLTMapLight Therapeutics, Inc.$237K0.05%0.03%NewQ4 2025
GBIOGeneration Bio Co.$142K0.03%0.37%NewQ4 2025
PRQRProQR Therapeutics N.V.$138K0.03%0.07%NewQ4 2025
APLTApplied Therapeutics, Inc.$41.1K0.01%0.28%NewQ4 2025
Q3 2025Reported Nov 13, 202514 positions
MRUSMerus N.V.$144M29.40%2.02%-2.2%Q4 2021
STOKStoke Therapeutics, Inc.$110M22.37%9.81%Not reportedQ3 2023
GHRSGH Research PLC$104M21.23%16.53%+27.5%Q2 2023
PTGXProtagonist Therapeutics, Inc$46.5M9.47%1.12%-4.5%Q1 2025
CGEMCullinan Therapeutics, Inc.$34.2M6.96%9.76%+31.0%Q2 2023
CCCCC4 Therapeutics, Inc.$15.8M3.21%9.57%Not reportedQ3 2023
TCRXTScan Therapeutics, Inc.$14.3M2.91%32.77%Not reportedQ2 2023
DTILPrecision Biosciences Inc$5.76M1.17%8.63%+0.6%Q4 2024
ADCTADC Therapeutics SA$5.3M1.08%1.18%NewQ3 2025
PASGPassage BIO, Inc.$5.01M1.02%19.62%+34.8%Q1 2022
DNLIDenali Therapeutics Inc.$3.8M0.77%0.18%NewQ3 2025
IBIOiBio, Inc.$874K0.18%5.21%-31.4%Q1 2024
ALLOAllogene Therapeutics, Inc.$677K0.14%0.24%-95.1%Q2 2024
DSGNDesign Therapeutics, Inc.$497K0.10%0.12%Not reportedQ1 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.